While the superior potency of IFN-β has been noted in other malignancies, demonstrating this principle specifically in BLCA is a critical and non-incremental advance that provides the necessary evidence to reconsider the current therapeutic development strategies. This evidence concerns the gene IFNB1 and bladder transitional cell carcinoma.